AprilBio Co Ltd
KOSDAQ:397030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AprilBio Co Ltd
Total Receivables
AprilBio Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
Total Receivables
₩1.8B
|
CAGR 3-Years
61%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Receivables
₩2T
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Receivables
₩6.3B
|
CAGR 3-Years
76%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Receivables
₩248.7m
|
CAGR 3-Years
296%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Receivables
₩38.4B
|
CAGR 3-Years
61%
|
CAGR 5-Years
70%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Receivables
₩59.6B
|
CAGR 3-Years
370%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
AprilBio Co Ltd
Glance View
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
See Also
What is AprilBio Co Ltd's Total Receivables?
Total Receivables
1.8B
KRW
Based on the financial report for Dec 31, 2025, AprilBio Co Ltd's Total Receivables amounts to 1.8B KRW.
What is AprilBio Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
126%
Over the last year, the Total Receivables growth was 1%. The average annual Total Receivables growth rates for AprilBio Co Ltd have been 61% over the past three years , 126% over the past five years .
